O	0	2	No
O	3	14	differences
O	15	22	between
B-intervention	23	32	Calendula
I-intervention	33	38	cream
O	39	42	and
B-control	43	50	aqueous
I-control	51	56	cream
O	57	59	in
O	60	63	the
O	64	74	prevention
O	75	77	of
B-condition	78	83	acute
I-condition	84	93	radiation
I-condition	94	98	skin
I-condition	99	108	reactions
O	108	109	-
O	109	110	-
O	110	117	results
O	118	122	from
O	123	124	a
O	125	135	randomised
O	136	143	blinded
O	144	149	trial
O	149	150	.

O	151	154	The
O	155	162	purpose
O	163	165	of
O	166	170	this
O	171	178	blinded
O	178	179	,
O	180	190	randomized
O	191	199	clinical
O	200	205	trial
O	206	209	was
O	210	212	to
O	213	220	compare
O	221	224	two
O	225	232	topical
O	233	239	agents
O	240	241	(
B-intervention	241	250	Calendula
I-intervention	251	257	Weleda
I-intervention	258	263	cream
O	264	266	vs
O	266	267	.
B-intervention	268	273	Essex
I-intervention	274	279	cream
O	279	280	)
O	281	283	in
O	284	292	reducing
O	293	296	the
O	297	301	risk
O	302	304	of
O	305	311	severe
O	312	317	acute
O	318	327	radiation
O	328	332	skin
O	333	342	reactions
O	343	344	(
O	344	348	ARSR
O	348	349	)
O	350	352	in
O	353	361	relation
O	362	364	to
O	365	373	adjuvant
O	374	386	radiotherapy
O	387	388	(
O	388	390	RT
O	390	391	)
O	392	395	for
O	396	402	breast
O	403	409	cancer
O	409	410	.

O	411	414	The
O	415	422	primary
O	423	431	endpoint
O	432	435	was
O	436	439	the
B-outcome-Measure	440	450	difference
I-outcome-Measure	451	453	in
I-outcome-Measure	454	464	proportion
I-outcome-Measure	465	467	of
I-outcome-Measure	468	476	patients
I-outcome-Measure	477	481	with
I-outcome-Measure	482	486	ARSR
O	486	487	,
O	488	496	assessed
O	497	501	with
O	502	505	the
O	506	515	Radiation
O	516	523	Therapy
O	524	532	Oncology
O	533	538	Group
O	538	539	/
O	539	542	The
O	543	555	Organization
O	556	559	for
O	560	568	Research
O	569	572	and
O	573	582	Treatment
O	583	585	of
O	586	592	Cancer
O	593	598	Acute
O	599	608	Radiation
O	609	618	Morbidity
O	619	626	Scoring
O	627	635	Criteria
O	636	637	(
O	637	641	RTOG
O	641	642	/
O	642	647	EORTC
O	648	653	scale
O	653	654	)
O	655	657	at
O	658	664	follow
O	664	665	-
O	665	667	up
O	667	668	.

O	669	672	The
O	673	682	secondary
O	683	692	endpoints
O	693	701	included
O	702	709	patient
O	710	718	reported
O	719	726	outcome
O	727	735	measures
O	735	736	;
B-outcome-Measure	737	744	Quality
I-outcome-Measure	745	747	of
I-outcome-Measure	748	752	Life
I-outcome-Measure	753	766	Questionnaire
O	767	768	(
O	768	771	QLQ
O	771	772	-
O	772	775	C30
O	775	776	)
O	776	777	,
B-outcome-Measure	778	783	Sleep
I-outcome-Measure	784	796	disturbances
O	797	798	(
O	798	801	MOS
O	801	802	-
O	802	807	sleep
O	808	821	questionnaire
O	821	822	)
O	823	826	and
B-outcome-Measure	827	835	symptoms
I-outcome-Measure	836	840	from
I-outcome-Measure	841	844	the
I-outcome-Measure	845	855	irradiated
I-outcome-Measure	856	860	area
O	861	862	(
O	862	868	visual
O	869	877	analogue
O	878	883	scale
O	883	884	)
O	884	885	.

O	886	894	Patients
O	894	895	'
O	896	907	experiences
O	908	911	and
O	912	921	adherence
O	922	924	to
O	925	928	the
O	929	936	topical
O	937	943	agents
O	944	948	were
O	949	953	also
O	954	963	evaluated
O	963	964	.

O	965	966	A
O	967	972	total
O	973	975	of
B-total-participants	976	979	420
O	980	988	patients
O	989	993	were
O	994	1004	randomised
O	1005	1008	and
B-total-participants	1009	1012	411
O	1013	1017	were
O	1018	1026	analysed
O	1026	1027	.

O	1028	1032	With
O	1033	1036	the
O	1037	1046	exception
O	1047	1049	of
O	1050	1058	previous
O	1059	1071	chemotherapy
O	1071	1072	,
O	1073	1076	the
O	1077	1086	treatment
O	1087	1093	groups
O	1094	1098	were
O	1099	1103	well
O	1104	1112	balanced
O	1112	1113	,
O	1114	1118	both
O	1119	1128	regarding
O	1129	1138	treatment
O	1138	1139	-
O	1140	1143	and
O	1144	1151	patient
O	1151	1152	-
O	1152	1159	related
O	1160	1167	factors
O	1167	1168	.

O	1169	1172	The
B-outcome	1173	1182	incidence
I-outcome	1183	1185	of
I-outcome	1186	1192	severe
I-outcome	1193	1197	ARSR
O	1198	1199	(
O	1199	1203	RTOG
O	1203	1204	/
O	1204	1209	EORTC
O	1210	1215	grade
O	1216	1217	â‰¤
O	1217	1218	2
O	1218	1219	)
O	1220	1222	at
O	1223	1226	the
O	1227	1233	follow
O	1233	1234	-
O	1234	1236	up
O	1237	1242	visit
O	1243	1246	was
B-iv-bin-percent	1247	1249	23
I-iv-bin-percent	1249	1250	%
O	1251	1252	(
O	1252	1253	n
O	1254	1255	=
B-intervention-participants	1256	1258	45
O	1258	1259	)
O	1260	1262	in
O	1263	1266	the
O	1267	1276	Calendula
O	1277	1282	group
O	1283	1286	and
B-cv-bin-percent	1287	1289	19
I-cv-bin-percent	1289	1290	%
O	1291	1292	(
O	1292	1293	n
O	1294	1295	=
B-control-participants	1296	1298	38
O	1298	1299	)
O	1300	1302	in
O	1303	1306	the
O	1307	1312	Essex
O	1313	1318	group
O	1318	1319	.

O	1320	1322	We
O	1323	1328	found
O	1329	1331	no
O	1332	1342	difference
O	1343	1345	in
B-outcome	1346	1352	severe
I-outcome	1353	1357	ARSR
O	1358	1365	between
O	1366	1369	the
O	1370	1376	groups
O	1377	1379	at
O	1380	1383	any
O	1384	1389	point
O	1390	1392	of
O	1393	1403	assessment
O	1403	1404	.

O	1405	1408	The
O	1409	1417	patients
O	1418	1426	reported
O	1427	1430	low
B-outcome	1431	1437	levels
I-outcome	1438	1440	of
I-outcome	1441	1445	skin
I-outcome	1446	1453	related
I-outcome	1454	1462	symptoms
O	1463	1466	and
O	1467	1469	no
O	1470	1483	statistically
O	1484	1495	significant
O	1496	1507	differences
O	1508	1515	between
O	1516	1519	the
O	1520	1526	groups
O	1527	1531	were
O	1532	1537	found
O	1537	1538	.

O	1539	1541	No
O	1542	1553	differences
O	1554	1556	in
O	1557	1561	ARSR
O	1562	1569	between
O	1570	1578	patients
O	1579	1589	randomised
O	1590	1592	to
O	1593	1602	Calendula
O	1603	1605	or
O	1606	1611	Essex
O	1612	1617	cream
O	1618	1621	was
O	1622	1627	found
O	1627	1628	.

O	1629	1633	ARSR
O	1634	1638	seem
O	1639	1641	to
O	1642	1644	be
O	1645	1646	a
O	1647	1657	relatively
O	1658	1665	limited
O	1666	1673	problem
O	1673	1674	,
O	1675	1683	probably
O	1684	1688	more
O	1689	1699	influenced
O	1700	1702	by
O	1703	1712	treatment
O	1713	1720	related
O	1721	1728	factors
O	1729	1733	than
O	1734	1736	by
O	1737	1743	choice
O	1744	1746	of
O	1747	1751	skin
O	1752	1756	care
O	1757	1765	products
O	1766	1768	in
O	1769	1773	this
O	1774	1781	patient
O	1782	1787	group
O	1787	1788	.
